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A bs tr ac t
Background
The genetic alterations responsible for an adverse outcome in most patients with 
acute myeloid leukemia (AML) are unknown.
Methods
Using massively parallel DNA sequencing, we identified a somatic mutation in 
DNMT3A, encoding a DNA methyltransferase, in the genome of cells from a patient 
with AML with a normal karyotype. We sequenced the exons of DNMT3A in 280 
additional patients with de novo AML to define recurring mutations.
Results
A total of 62 of 281 patients (22.1%) had mutations in DNMT3A that were predicted 
to affect translation. We identified 18 different missense mutations, the most com-
mon of which was predicted to affect amino acid R882 (in 37 patients). We also identi-
fied six frameshift, six nonsense, and three splice-site mutations and a 1.5-Mbp dele-
tion encompassing DNMT3A. These mutations were highly enriched in the group of 
patients with an intermediate-risk cytogenetic profile (56 of 166 patients, or 33.7%) 
but were absent in all 79 patients with a favorable-risk cytogenetic profile (P<0.001 
for both comparisons). The median overall survival among patients with DNMT3A 
mutations was significantly shorter than that among patients without such muta-
tions (12.3 months vs. 41.1 months, P<0.001). DNMT3A mutations were associated 
with adverse outcomes among patients with an intermediate-risk cytogenetic pro-
file or FLT3 mutations, regardless of age, and were independently associated with a 
poor outcome in Cox proportional-hazards analysis.
Conclusions
DNMT3A mutations are highly recurrent in patients with de novo AML with an in-
termediate-risk cytogenetic profile and are independently associated with a poor 
outcome. (Funded by the National Institutes of Health and others.)
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Whole-genome sequencing is an unbiased approach for discovering so-matic variations in cancer genomes. We 
recently reported the DNA sequence and analysis 
of the genomes of two patients with acute my-
eloid leukemia (AML) with a normal karyotype.1,2 
We did not find new recurring mutations in the 
first study but did observe a recurrent mutation in 
IDH1, encoding isocitrate dehydrogenase 1, in the 
second study.2 Subsequent work has confirmed 
and extended this finding, showing that mutations 
in IDH1 and related gene IDH2 are highly recur-
rent in patients with an intermediate-risk cytoge-
netic profile (20 to 30% frequency) and are associ-
ated with a poor prognosis in some subgroups of 
patients.3-5 Improvements in sequencing tech-
niques prompted us to reevaluate the first case with 
deeper sequence coverage, during which we dis-
covered a frameshift mutation in the DNA methyl-
transferase gene DNMT3A.
The human genes DNMT1, DNMT3A, and 
DNMT3B encode DNA methyltransferases, enzymes 
that catalyze the addition of a methyl group to 
the cytosine residue of CpG dinucleotides. Clus-
ters of CpG dinucleotides (islands) are concen-
trated in regions upstream of genes; increased 
methylation of these CpG islands is often associ-
ated with reduced expression of the downstream 
gene. Aberrant DNA methylation has long been 
hypothesized to contribute to the pathogenesis of 
cancer.6-9 Although cancer genomes tend to be 
globally hypomethylated, as compared with nor-
mal tissues, hypermethylation of CpG islands in 
the promoters of tumor-suppressor genes is com-
mon in many tumors.
Genomewide methylation profiling of AML 
samples with the use of microarrays has shown 
that subgroups of samples have similar methyla-
tion patterns.10 Samples obtained from patients 
with myelodysplastic syndromes have a pattern of 
aberrant hypermethylation, as compared with that 
of de novo AML, which is defined as newly diag-
nosed disease with no history of chemotherapy 
or radiation therapy and no history of a myelo-
dysplastic syndrome or a myeloproliferative neo-
plasm.11 DNA methyltransferase inhibitors are 
widely used to treat patients with AML and myelo-
dysplastic syndromes, although the response rate 
is low, the response is unpredictable in individ-
ual patients, and it is not clearly associated with 
methylation status.12-14 In addition, in a recent 
study,15 higher expression of miR-29b, a microRNA 
that targets DNMT3A messenger RNA (mRNA), in 
AML blasts was associated with an improved 
clinical response to the DNA methyltransferase 
inhibitor decitabine.
After discovering a frameshift mutation in 
DNMT3A with whole-genome sequencing, we con-
ducted a study to determine whether DNMT3A is 
recurrently mutated in AML samples and whether 
DNMT3A mutations are associated with poor sur-
vival.
Me thods
We have described the clinical features of the pro-
band previously.1 The patient’s next of kin con-
sented to the sequencing of her tumor and skin 
genomes on the basis of a protocol that was ap-
proved by the institutional review board and that 
explicitly described the privacy issues of whole-
genome sequencing. We have also described the 
methods that we used for sequencing, determin-
ing whether mutations were recurrent, expression 
analysis, and outcomes analysis.2 Methods that are 
used in whole-genome analysis of 5-methylcyto-
sine content and methylated DNA immunoprecip-
itation-chip (MeDIP-chip) analysis are described 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org.
R esult s
Identification of DNMT3A Mutations
We previously sequenced the AML genome of a 
sample obtained from Patient 933124 and ob-
tained short single-end reads, yielding 98 billion 
base pairs of sequence and 91.2% diploid cover-
age of the genome.1 In this study, we obtained 
116.4 billion base pairs with paired-end reads 
from the genome of the relapsed tumor, yielding 
99.6% diploid coverage of the genome. The im-
proved sequence coverage with paired-end reads 
and improved mutation calling algorithms allowed 
us to identify several nonsynonymous tier 1 muta-
tions that we did not detect in our initial se-
quencing effort, including a 1-base-pair deletion 
in DNMT3A. We subsequently verified that this 
mutation was also present in the dominant clone 
of the original AML sample obtained at presenta-
tion (see Supplementary Appendix for details). 
This deletion causes a frameshift in the codon 
encoding lysine at amino acid position 723, 
which predicts the synthesis of 56 novel amino 
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acids (i.e., amino acids that are not encoded by 
nonmutated DNMT3A at positions including and 
beyond amino acid position 723), followed by an 
in-frame, premature stop codon.
DNMT3A Mutations in AML
We sequenced the exons of DNMT3A and DNMT3L 
(DNMT3L forms heterodimers with both DNMT3A 
and its homologue, DNMT3B) by polymerase-
chain-reaction (PCR) amplification and Sanger 
sequencing of samples from 188 patients with de 
novo AML, which were banked at Washington Uni-
versity. (Primer sequences are provided in the 
Supplementary Appendix.) All 188 tumors had 
matched normal DNA samples available for analy-
sis. We obtained 94 additional AML samples from 
the Cancer and Leukemia Group B (CALBG); 
matched normal tissue was not available for these 
samples. The characteristics of all 282 patients, 
the treatments they received, and the mutations 
found are provided in the Supplementary Appen-
dix. Although these patients were not treated 
uniformly, the prevalence of common AML mu-
tations among them was typical, and the clinical 
outcomes were similar to those in other series of 
patients that have been described recently.
We amplified and sequenced all 24 exons of 
DNMT3A for 281 of the 282 tumor samples. Of 
these samples, 62 (22.1%) had mutations predict-
ing translational consequences; 5 of these 62 tu-
mors had two independent mutations, with none 
of these mutations predicted to affect amino acid 
position 882. We determined that all mutations 
in the tumors obtained from Washington Univer-
sity were somatic events by virtue of their absence 
in DNA sequences obtained from matched skin 
samples; a summary of all confirmed somatic 
mutations is shown in Figure 1. We observed seven 
novel sequence changes in DNMT3A in the CALGB 
sample set but could not determine whether they 
were somatic changes without matched DNA from 
unaffected tissue. (Putative somatic CALGB mu-
tations are listed in Fig. 1 in the Supplementary 
Appendix.) None of the novel variants that were 
detected in the CALGB tumors have previously 
been identified as single-nucleotide polymor-
phisms. We identified 18 different missense mu-
tations across both sets of tumors. The most com-
mon missense mutations are predicted to affect 
amino acid R882 (in 37 tumors) (Table 2 in the 
Supplementary Appendix). A total of 27 tumors 
had the R882H variant, 7 had R882C, 2 had R882P, 
and 1 had R882S. We also observed six frame-
shift, six nonsense, and three splice-site mutations 
and a 1.5-Mb deletion that included DNMT3A and 
eight other genes (Fig. 2 in the Supplementary 
Appendix). We observed no somatic mutations in 
the coding exons of DNMT3L in 188 samples that 
were tested.
The relationship between DNMT3A mutations 
and other common mutations in AML genomes 
is shown in Table 1 and Figure 2. Mutations in 
FLT3, NPM1, and IDH1 were significantly enriched 
in samples with DNMT3A mutations. No DNMT3A 
mutations (and likewise no NPM1 or IDH1/2 mu-
tations) were found in 79 AML samples with cy-
togenetic findings associated with a favorable 
outcome (P<0.001). Likewise, none of the 11 pa-
tients with structural variations involving 11q23, 
the location of the mixed-lineage leukemia gene, 
had DNMT3A mutations. DNMT3A mutations were 
significantly enriched in 56 of 166 patients with 
a cytogenetic profile associated with intermedi-
ate risk (33.7%, P<0.001), including 44 of 120 pa-
tients with a normal cytogenetic profile (36.7%, 
P<0.001), as well as 20 of 61 patients with the M4 
subtype (32.8%, P = 0.04) and 12 of 21 patients 
with the M5 subtype (57.1%, P<0.001), according 
to the French–American–British (FAB) classifica-
tion system. White-cell counts at presentation were 
significantly higher in patients with R882 muta-
tions than in other patients. The single patient 
with a FAB M3 morphologic subtype and a DNMT3A 
mutation (Patient 287), who died 2.2 months af-
ter presentation, had a normal cytogenetic pro-
file and did not have the characteristic expression 
signature of t(15;17) AML.16,17
We obtained expression array data from 180 
of the 188 samples obtained from Washington 
University (GeneChip Human Genome U133 Plus 
2.0 Array, Affymetrix). We identified the expres-
sion of genes encoding DNA methyltransferases 
in AML samples and in normal hematopoietic cells 
with these data (Fig. 3 in the Supplementary Ap-
pendix). DNMT3A was expressed in all 180 AML 
samples and in normal human CD34+ bone mar-
row cells. Its expression decreased with terminal 
myeloid differentiation. We observed no differ-
ence in the levels of DNMT3A expression between 
AML samples with DNMT3A mutations and those 
without DNMT3A mutations. Likewise, DNMT3B 
and DNMT1 were both highly expressed in AML 
samples and normal CD34+ cells. The single 
DNMT3L probe set on the expression array revealed 
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no expression of DNMT3L in any sample; however, 
spliced DNMT3L was detected with transcriptome 
sequencing of AML cells from several patients 
(data not shown).
To determine whether the mutant DNMT3A al-
leles are expressed, we amplified the target regions 
from 21 primary tumor samples from bone mar-
row using reverse-transcriptase PCR and then se-
quenced the amplicons using the Roche 454-Tita-
nium platform to obtain deep read counts (Table 3 
and Fig. 4 in the Supplementary Appendix). For 
most of the samples, the proportion of comple-
mentary DNA (cDNA) sequence reads containing 
the variant allele was about 50%, suggesting that 
the variant and wild-type alleles are expressed at 
nearly equal levels. One nonsense mutation (E477*) 
and one frameshift mutation (M315fs) were not 
detected in the cDNA samples, suggesting that 
mRNAs carrying these variants are subject to 
nonsense-mediated decay. There was no evidence 
of homozygous loss of DNMT3A expression for any 
of the five samples carrying two mutations. We did 
not detect variant cDNAs carrying the missense 
allele (A741V) or the nonsense allele (E477*) in the 
sample from Subject 246634, although we readily 
detected cDNA from the nonmutated allele in this 
sample (Table 3 in the Supplementary Appendix). 
We suspect that A741V and E477* were on the 
same allele and thus were equally affected by 
nonsense-mediated decay.
Patterns of Mutations
We have recently sequenced the genomes of 38 
cytogenetically normal samples of de novo AML, 
with an average of more than 25 times genome 
coverage obtained for each tumor and matched 
normal skin genome. Of these genomes, 11 have 
mutations in DNMT3A, but no mutations were de-
tected in DNMT3L, DNMT1, or DNMT3B (data not 
shown). We identified with high confidence somat-
ic single-nucleotide variants in each genome and 
determined that the total number of these vari-
ants was not significantly influenced by DNMT3A 
mutation status (Fig. 5 in the Supplementary Ap-
pendix). Furthermore, the types of mutations de-
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Figure 1. DNMT3A Mutations in 188 Patients with Acute Myeloid Leukemia (AML).
Shown are data from samples banked at Washington University that were obtained from 188 patients with AML. All mutations that are 
shown were confirmed to be somatic. The locations of the PWWP domain (characterized by the presence of a highly conserved proline–
tryptophan–tryptophan –proline motif), the ADD (ATRX, DNMT3, and DNMT3L)-type zinc finger (ZNF) domain, and the methyltransfer-
ase (MTase) domain are shown. Each patient with a DNMT3A mutation is designated with a circle. The deletion that is noted at position 
1 is a 1.5-Mbp deletion that includes DNMT3A and part or all of eight other genes (for details, see Fig. 2 in the Supplementary Appendix).
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were not associated with DNMT3A mutation sta-
tus (Table 4 and Fig. 6 in the Supplementary Ap-
pendix).
DNA Methylation
To determine whether the 5-methylcytosine con-
tent was altered in AML genomes with DNMT3A 
mutations, we hydrolyzed genomic DNA derived 
from the bone marrow of patients with AML to 
nucleoside monophosphates and assayed 5-methyl-
2′-deoxycytidine 5′-monophosphate using liquid 
chromatography–tandem mass spectrometry (see 
the Supplementary Appendix). The mean (±SD) 
5-methylcytosine content of each genome with a 
















Age at study entry — yr 47.8±16.6 52.1±13.1 54.6±14.8 53.1±13.7 0.02‡
Race — no. (%)§ 0.58¶
White 195 (89) 34 (92) 21 (84) 55 (89)
Black 18 (8) 2 (5) 2 (8) 4 (6)
Other 6 (3) 1 (3) 2 (8) 3 (5)
Male sex — no. (%) 125 (57) 17 (46) 11 (44) 28 (45) 0.10‖
Bone marrow blasts at diagnosis — % 69.4±18.6 73.5±16.3 63.6±18.0 69.5±17.6 0.96‡
Normal karyotype — no./total no. (%) 76/216 (35) 27/36 (75) 17/25 (68) 44/61 (72) <0.001‖
White-cell count at diagnosis — (×10−3/mm3) <0.001**
No. of patients 142 27 18 45
Mean 39.3±65.8 78.0±57.3 29.8±29.4 58.7±53.3
Median 11.8 72.6 19.2 46.4
Cytogenetic risk — no./total no. (%)†† <0.001¶
Favorable 79/215 (37) 0/36 0/24 0/60
Intermediate 110/215 (51) 34/36 (94) 22/24 (92) 56/60 (93)
Adverse 26/215 (12) 2/36 (6) 2/24 (8) 4/60 (7)
AML subtype — no. (%)
M3 47 (21) 1 (3) 0 1 (2) <0.001‖
M4 41 (19) 14 (38) 6 (24) 20 (32) 0.02‖
M5 9 (4)  9 (24) 3 (12) 12 (19) <0.001¶
Mutation — no./total no. (%)
NPM1 27/216 (13) 24/37 (65) 13/25 (52) 37/62 (60) <0.001‖
FLT3 48/217 (22) 17/36 (47)  8/25 (32) 25/61 (41) 0.003‖
IDH1 12/218 (6) 10/37 (27)  3/25 (12) 13/62 (21) <0.001‖
IDH2 13/217 (6) 1/37 (3)  6/25 (24) 7/62 (11) 0.15‖
t(15;17) 45/219 (21) 0/37 0/25 0/62 <0.001‖
t(8;21) 12/219 (5) 0/37 0/25 0/62 0.07¶
inv(16) 20/219 (9) 0/37 0/25 0/62 0.01¶
*  Plus–minus values are means ±SD. DNMT denotes DNA methyltransferase.
†  P values are for the comparisons between no DNMT3A mutations and any DNMT3A mutation.
‡  The P value was calculated by means of Student’s t-test.
§  Race was self-reported.
¶  The P value was calculated by means of Fisher’s exact test.
‖  The P value was calculated by means of Pearson’s chi-square test.
** The P value was calculated by means of the Wilcoxon test.
†† The Cancer and Leukemia Group B classification system was used to stratify risk on the basis of cytogenetic findings.16
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Mutation Group B Mutation Group C
Figure 2. Relationship between DNMT3A Mutations and Other Common Mutations in 188 Patients with Acute 
Myeloid Leukemia (AML).
Shown is the mutation status of each of 188 patients with AML on the basis of sequencing results shown in Figure 1. 
Red indicates the presence of the specified mutation in the designated patient, and green the absence of the muta-
tion. For DNMT3A mutations, the presence of any R882 variant is shown in tan, and all other DNMT3A mutations 
are shown in blue. DNMT3A, NPM1, and IDH1/2 mutations were not detected in any sample with t(15;17), t(8;21), 
complex t(8;21), or inv(16). In samples with DNMT3A mutations, mutations in FLT3 (either internal tandem duplica-
tions or mutations at amino acid position D835), NPM1, and IDH1 were significantly enriched. Cytogenetic risk 
groups are shown at the bottom of the graph, with yellow indicating favorable risk, orange intermediate risk, and 
purple adverse risk. Black boxes indicate that no data were available for that sample. Mutation groups as defined by 
these data are designated at the top of the graph. Samples in mutation group A have cytogenetic findings associated 
with favorable risk and have only FLT3 mutations among the five commonly mutated AML genes. Samples in muta-
tion group B are highly enriched for mutations in the five commonly mutated AML genes that are associated with 
intermediate risk. Samples in mutation group C have no mutations in any of the five common AML genes, suggest-
ing that a different set of mutations may contribute to the pathogenesis in this group.
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DNMT3A mutation was virtually identical to that 
of AML genomes without DNMT3A mutations (wild 
type, 4.89±0.57%; any DNMT3A mutation, 4.77±
0.50%; P = 0.45) (Table 5 and Fig. 7 in the Supple-
mentary Appendix).
We determined the methylation patterns of five 
AML genomes with the R882H mutation and five 
matched AML genomes (i.e., with the same FAB 
subtypes and myeloblast percentages) with non-
mutated DNMT3A, using MeDIP-chip analysis. 
Nearly all the methylated regions were similar 
among the 10 samples (Fig. 8A in the Supplemen-
tary Appendix), with only a small number of ex-
ceptions (Table 6 and Fig. 8B and 9 in the Sup-
plementary Appendix). A total of 182 genomic 
regions had significantly different methylation 
levels (at specific genomic locations) associated 
with DNMT3A mutation status. All 182 regions had 
significantly reduced methylation on average in the 
mutant genomes. There was no consistent corre-
lation between any of the differentially methylated 
regions and altered expression of “nearest neigh-
bor” genes (data not shown).
Gene Expression and DNMT3A Mutations
We performed unsupervised clustering, using ex-
pression data from 180 of the 188 samples banked 
at Washington University (Fig. 10 in the Supple-
mentary Appendix). Although multiple expression 
clusters were clearly identified, none were clearly 
defined by DNMT3A mutation status. Similar re-
sults were obtained with the subgroup of 76 arrays 
from AML samples with a normal cytogenetic pro-
file (Fig. 11 in the Supplementary Appendix).
Clinical Outcome and DNMT3A Mutations
We determined event-free and overall survival for 
all 281 patients with AML for whom DNMT3A mu-
tation status was known. The two metrics were 
very similar, so only overall survival is reported. 
Patients with DNMT3A mutations had signifi-
cantly worse survival (Fig. 3A). The presence of a 
DNMT3A mutation was also associated with worse 
survival among patients with a normal cytogenet-
ic profile (P = 0.007) (Fig. 3B) and those with an 
intermediate-risk profile (P = 0.006) (Fig. 12 in the 
Supplementary Appendix). When patients with 
FLT3 internal tandem duplication mutations were 
classified according to DNMT3A status, those car-
rying a DNMT3A mutation had a significantly worse 
outcome (P<0.001) (Fig. 3C). Finally, DNMT3A mu-
tations were associated with an adverse outcome 
for patients regardless of age (P<0.001 for ≤60 
years and P = 0.03 for >60 years), although patients 
with DNMT3A mutations who were older than 60 
years had an extremely poor outcome (Fig. 3D). 
Data on DNMT3A mutations and overall survival 
among patients with all combinations of common 
AML mutations (NPM1, IDH1/2, and FLT3) are pro-
vided in Figures 13, 14, and 15 in the Supplemen-
tary Appendix; Cox proportional-hazards models 
showed that the variables that were independent-
ly associated with overall survival were DNMT3A 
mutations, FLT3 mutations, and age.
Discussion
DNMT3A mutations are recurrent in patients with 
AML and are associated with poor event-free and 
overall survival, independently of age and the pres-
ence of FLT3 or NPM1 mutations and regardless of 
the type of mutation or genetic location. This find-
ing strongly suggests that DNMT3A mutations are 
probably relevant to the pathogenesis of AML. 
DNMT3A mutations do not cause genomic insta-
bility (since most genomes with mutations have a 
normal cytogenetic profile and an unaltered num-
ber of total mutations), do not alter total 5-methyl-
cytosine content or global patterns of methylation, 
and do not dramatically alter gene expression. Cur-
rently, the only clue regarding the pathogenetic 
mechanism is strong selection against DNMT3A 
mutations (and also IDH1/2 and NPM1 mutations) 
in patients who have a favorable-risk cytogenetic 
profile, suggesting a biologic relationship that is 
not random (Fig. 2).
In patients with AML, there are two major 
classes of DNMT3A mutations. The first class is 
the highly recurrent set of mutations at R882, as 
recently described in 3 of 74 AML samples tested 
by Yamashita et al.18 (The low prevalence of this 
variant in that study could reflect a different sam-
ple population or a lower sensitivity of mutation 
detection.) The second class is represented by all 
the other mutations in this gene. The locations of 
mutations in DNMT3A are similar to those of 
DNMT3B mutations associated with the immuno-
deficiency, centromere instability, and facial anom-
alies (ICF) syndrome.19,20
Recurrent mutations at a single amino acid 
position suggest a gain-of-function mechanism, 
although widely divergent mutations at many 
positions in a gene generally suggest loss of 
function, a pattern seen for many classic tumor-
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suppressor genes (e.g., TP53 and BRCA1). In-
deed, several of the non-R882 mutations clearly 
cause loss of function in DNMT3A. A gain-of-
function property that is induced by the R882 
mutation is not yet apparent.
The MeDIP-chip experiments revealed a signifi-
cant reduction in DNA methylation at 182 genom-
ic locations, suggesting that R882 mutations may 
act in a dominant-negative fashion to reduce the 
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Figure 3. Overall Survival among Patients with Acute Myeloid Leukemia (AML) with DNMT3A Mutations.
Panel A shows the overall survival among all 281 patients, including 62 with a DNMT3A mutation and 219 without a DNMT3A mutation. 
Panel B shows the overall survival of 120 patients with normal karyotypes, including 44 with a DNMT3A mutation and 76 without a 
DNMT3A mutation. Panel C shows the overall survival of 54 patients with an FLT3 internal tandem duplication mutation, including 16 
with a DNMT3A mutation and 38 without a DNMT3A mutation. Panel D shows the overall survival of all 281 patients stratified accord-
ing to DNMT3A mutation status and age; 72 patients were over the age of 60 years and 209 were 60 years of age or younger. All P val-
ues, which are for the comparison between any DNMT3A mutation and no mutation, were calculated by means of the log-rank test.
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pothesis is supported by the fact that all R882 
mutations are heterozygous and by observations 
that this mutation reduces methyltransferase ac-
tivity in vitro.18,21 Both the R882H and R882C 
mutations are caused by a C-to-T transition at a 
CpG dinucleotide (R882H on the noncoding strand 
and R882C on the coding strand), suggesting that 
these mutations may be caused by the deamina-
tion of methylcytosine on either strand of this CpG 
dinucleotide.22 Many DNMT3A mutations are pre-
dicted to cause changes in the DNA binding 
groove of DNMT3A, and some are predicted to 
change its interaction with DNMT3L (Fig. 16 in the 
Supplementary Appendix). However, it is possible 
that R882 mutations alter functions of DNMT3A 
that are not yet fully understood, including its 
ability to bind to other proteins involved in tran-
scriptional regulation and localization to chroma-
tin regions containing methylated DNA.23-26 In any 
case, all DNMT3A mutations are associated with 
poor overall survival, suggesting that they have an 
important common effect on the potential of AML 
cells to cause lethal disease.
The association between DNMT3A mutations 
and mutations in the four other most commonly 
mutated genes in AML (FLT3, NPM1, IDH1, and 
IDH2) is evident, as shown in Figure 2. A large 
proportion of patients with an intermediate-risk 
cytogenetic profile had mutations in one or more 
of these genes (mutation group B in Fig. 2). How-
ever, many patients with an intermediate- or 
adverse-risk cytogenetic profile had no mutations 
in any of these genes (mutation group C), which 
was not a random finding (P<0.001). Patients in 
mutation group C had outcomes similar to those 
of patients in mutation group B with one or two 
mutations (Fig. 17 in the Supplementary Appen-
dix) but may have a unique set of driver muta-
tions. These may include some of the less com-
monly mutated AML genes (e.g., CEBPA, RUNX1, 
NRAS, and KRAS), although whole-genome se-
quencing may ultimately be required to identify 
the key mutations in this group.
Remarkably, no DNMT3A mutations were found 
in the group of 79 patients with a favorable-risk 
cytogenetic profile (Table 1 and Fig. 2), which 
includes patients with t(15;17), t(8;21), and inv(16). 
Mutations in NPM1, IDH1, and IDH2 were not de-
tected in these patients either, a finding that is 
consistent with data reported in other stud-
ies.4,27-30 The virtual exclusion of mutations in 
these four genes in patients with a favorable-risk 
profile is not random and may reflect the leuke-
mogenic properties of the fusion proteins created 
by these chromosomal rearrangements. The PML-
RARA fusion protein, which is created by t(15;17), 
physically interacts with DNMT3A, and AML-ETO, 
which is created by t(8;21), interacts with DNMT1; 
both fusion proteins alter the methylation of spe-
cific promoters.31-33 Both PML and DNMT3A regu-
late telomere function, and all-trans retinoic acid, 
which is part of the therapy for patients with 
t(15;17), down-regulates DNMT3A expression.34,35 
Together, these data suggest that DNMT3A muta-
tions and the favorable-risk fusion oncogenes (e.g., 
PML-RARA and AML-ETO) may not be found in 
the same AML genomes because they both act to 
alter the function of DNA methyltransferases and 
are therefore redundant. However, the outcomes 
for patients with DNMT3A mutations and those 
with a favorable-risk cytogenetic profile are dra-
matically different, for reasons that are currently 
unclear.
DNMT3A mutations do not change 5-methylcy-
tosine content in AML genomes, and the R882H 
mutation appears to minimally perturb the methy-
lation of CpG islands. We did not detect changes 
in DNA methylation that were directly correlated 
with local changes in gene expression. These data 
might suggest that DNMT3A mutations do not 
directly affect the cytosine methyltransferase 
properties of DNMT3A. However, a recent study 
has suggested that DNMT3A may alter the methy-
lation of nonpromoter-associated CpG regions, 
affecting gene expression indirectly.36 Many fur-
ther experiments will be required to define the 
precise mechanisms by which these mutations act.
The discovery of highly recurrent mutations in 
DNMT3A may provide a new tool for the classifi-
cation of intermediate-risk AML. If these data are 
reproduced in other series, clinical trials designed 
to assess the effects of early intensification of 
treatment in patients with DNMT3A mutations may 
be warranted. In our small series, allogeneic trans-
plantation provided a significant benefit for pa-
tients with DNMT3A mutations (Fig. 18 in the 
Supplementary Appendix). The careful analysis of 
many additional AML samples with unbiased ge-
nomic methods may reveal changes in methylation 
or expression that help to define the mechanisms 
of action of DNMT3A mutations.
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